Gera Neufeld

Prof. Gera Neufeld

Technion – Israel Institute of Technology, Haifa, Israel
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in The FASEB Journal
Verified
Journal Article
Closed access
GNGera Neufeld
Gera Neufeld
TCTzafra Cohen
Tzafra Cohen
SGStela Gengrinovitch
Stela Gengrinovitch
ZPZoya Poltorak
Zoya Poltorak

26 June 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
GNGera Neufeld
Gera Neufeld
OKOfra Kessler
Ofra Kessler

1 February 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
OKOfra Kessler
Ofra Kessler
NSNiva Shraga-Heled
Niva Shraga-Heled
TLTali Lange
Tali Lange
NGNoga Gutmann-Raviv
Noga Gutmann-Raviv
ESEdmond Sabo
Edmond Sabo
GNGera Neufeld
Gera Neufeld
The neuropilin-1 (np1) and neuropilin-2 (np2) receptors form complexes with type-A plexins. These complexes serve as signaling receptors for specific class-3 semaphorins. Np1 and np2 function in addition as receptors for heparin-binding forms of vascular endothelial growth factor (VEGF), such as VEGF165. Human umbilical vein endothelial cells (HUVEC) express tyrosine-kinase receptors for VEGF and basic fibroblast growth factor (bFGF), as well as np1, np2, and several type-A plexins. We have found that semaphorin-3F (s3f), a semaphorin which signals through the np2 receptor, was able to inhibit VEGF165, as well as bFGF-induced proliferation of HUVECs. Furthermore, s3f inhibited VEGF as well as bFGF-induced phosphorylation of extracellular signal-regulated kinase-1/2. Our experiments indicate that bFGF does not bind to neuropilins, nor does s3f inhibit the binding of bFGF to FGF receptors. It is therefore possible that s3f inhibits the activity of bFGF by a mechanism that requires active s3f signal transduction rather than by inhibition of bFGF binding to FGF receptors. s3f also inhibited VEGF165, as well as bFGF-induced in vivo angiogenesis as determined by the alginate micro-encapsulation and Matrigel plug assays. Overexpression of s3f in tumorigenic human HEK293 cells inhibited their tumor-forming ability but not their proliferation in cell culture. The tumors that did develop from s3f-expressing HEK293 cells developed at a much slower rate and had a significantly lower concentration of tumor-associated blood vessels, indicating that s3f is an inhibitor of tumor angiogenesis.

1 September 2005 in Journal of Hepatology
Verified
Journal Article
Closed access
ZVZehava Vadasz
Zehava Vadasz
OKOfra Kessler
Ofra Kessler
GAGal Akiri
Gal Akiri
SGStela Gengrinovitch
Stela Gengrinovitch
HKHerbert M. Kagan
Herbert M. Kagan
GNGera Neufeld
Gera Neufeld

1 January 2002
Verified
Book Chapter
Closed access
PDF file
GNGera Neufeld
Gera Neufeld
OKOfra Kessler
Ofra Kessler
YHYael Herzog
Yael Herzog

26 September 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BKBoaz Kigel
Boaz Kigel
AVAsya Varshavsky
Asya Varshavsky
OKOfra Kessler
Ofra Kessler
GNGera Neufeld
Gera Neufeld
The class-3 semaphorins (sema3s) include seven family members. Six of them bind to neuropilin-1 (np1) or neuropilin-2 (np2) receptors or to both, while the seventh, sema3E, binds to the plexin-D1 receptor. Sema3B and sema3F were previously characterized as tumor suppressors and as inhibitors of tumor angiogenesis. To determine if additional class-3 semaphorins such as sema3A, sema3D, sema3E and sema3G possess anti-angiogenic and anti-tumorigenic properties, we expressed the recombinant full length semaphorins in four different tumorigenic cell lines expressing different combinations of class-3 semaphorin receptors. We show for the first time that sema3A, sema3D, sema3E and sema3G can function as potent anti-tumorigenic agents. All the semaphorins we examined were also able to reduce the concentration of tumor associated blood vessels although the potencies of the anti-angiogenic effects varied depending on the tumor cell type. Surprisingly, there was little correlation between the ability to inhibit tumor angiogenesis and their anti-tumorigenic activity. None of the semaphorins inhibited the adhesion of the tumor cells to plastic or fibronectin nor did they modulate the proliferation of tumor cells cultured in cell culture dishes. However, various semaphorins were able to inhibit the formation of soft agar colonies from tumor cells expressing appropriate semaphorin receptors, although in this case too the inhibitory effect was not always correlated with the anti-tumorigenic effect. In contrast, the anti-tumorigenic effect of each of the semaphorins correlated very well with tumor cell expression of specific signal transducing receptors for particular semaphorins. This correlation was not broken even in cases in which the tumor cells expressed significant concentrations of endogenous semaphorins. Our results suggest that combinations of different class-3 semaphorins may be more effective than single semaphorins in cases in which tumor cells express more than one type of semaphorin receptors.